Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2025-03-27
• Target enrollment: 0
• Participant gender: All

Summary

Treatment for patients with high-risk breast cancer diagnoses is based on chemotherapy drugs with side effects. Dexamethasone is a drug that is part of the arsenal of pre-chemotherapy medications to prevent adverse events resulting from treatment, however common endocrine pathological conditions resulting from high doses of this corticoid are clinically evident in these individuals. The aim of this study is to evaluate the omission of corticosteroid doses as a pre-medication in cancer treatment after the second week of treatment with taxane in a curative setting.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto do Cancer do Estado de São Paulo

Criteria

Inclusion Criteria:

• Patients from the oncology services of ICESP and its Osasco unit.

• Over 18 years of age.

• Diagnosed with breast cancer who will be treated with an ACT Icesp scheme in the setting with curative intent (neoadjuvant and adjuvant).

Exclusion Criteria:

• Patients with significant cognitive impairment that prevents the questionnaire from being applied.

• Patients who are not fluent in Portuguese, or illiterate, who did not sign the ICF.

• ECOG 3 and KPS <70%.

• Metastatic patients, with the presence of other important morbidities that may interfere with laboratory findings.

• Patients with chronic use of steroidal and non-steroidal anti-inflammatory drugs.